|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2010-2-10
|
|
pubmed:abstractText |
Acute myeloid leukemia (AML) is a heterogeneous group of clonal disorders which is treated with similar regimens despite the heterogeneity. The treatment approach for many years has used combination chemotherapy, with usually an anthracycline and cytarabine as the foundation. In the present review we will present new data from recently completed trials that have demonstrated advances in the treatment of AML.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1531-7048
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
79-84
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20087177-Aminoglycosides,
pubmed-meshheading:20087177-Anthracyclines,
pubmed-meshheading:20087177-Antibodies, Monoclonal,
pubmed-meshheading:20087177-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:20087177-Antineoplastic Agents,
pubmed-meshheading:20087177-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20087177-Dose-Response Relationship, Drug,
pubmed-meshheading:20087177-Drug Administration Schedule,
pubmed-meshheading:20087177-Drug Delivery Systems,
pubmed-meshheading:20087177-Humans,
pubmed-meshheading:20087177-Leukemia, Myeloid, Acute
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Induction therapy in acute myeloid leukemia: intensifying and targeting the approach.
|
|
pubmed:affiliation |
Department of Blood and Marrow Transplantation, Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. hugo.fernandez@moffitt.org
|
|
pubmed:publicationType |
Journal Article,
Review
|
